Efficacy and safety of liraglutide for perioperative blood glucose control in diabetic subjects within enhanced recovery after surgery (ERAS) protocols

Not Applicable

• Conditions: type 2 diabetes

• Registration Number: JPRN-UMIN000031070
• Lead Sponsor: Takatsuki redcross hospital

Brief Summary

iraglutide was shown to be a more effective option than insulin therapy because (1) glycemic levels were more stable; (2) the number of patients requiring additional insulin according to the insulin sliding scale was significantly smaller (p = 0.005); (3) the insulin dosage required on the day of surgery was significantly smaller (p = 0.004); (4) the additional insulin volume required was significantly less for patients throughout the perioperative period (p = 0.001).

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2016-08-31
• Study Start: 2018-01-31
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who were to undergo gastrointestinal or neurosurgical procedures were excluded. Patients who tested positive for anti-GAD (glutamate decarboxylase) antibodies or with elevated ALT (2 times upper normal range) were excluded from the study. Patients with autonomic neuropathy or recurrent severe hypoglycemia were also excluded. Patients who had been administered any drug except for oral antidiabetic drugs (OADs), which could interfere with glucose level or bodyweight (i.e. systemic corticosteroids, orlistat or sibutramine), were also excluded. Patients who had been administered sGLT-2 inhibitor or thiazolidinediones were excluded because these medicines could interfere with accurate bodyweight changes

Study & Design

• Study Type: Interventional
• Study Design: Not specified